Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid arthritis (RA). METHODS: Data of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in haemoglobin level. RESULTS: At baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in TIBC and haemoglobin. CONCLUSIONS: Inflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the inflammatory anaemia of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Tocilizumab administration also lowered hepcidin and improved anemia in rheumatoid arthritis patients (Isaacs et al., 2013; Song et al., 2013) and in a monkey arthritis model (Hashizume et al., 2010).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Isaacs et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin acts as a gatekeeper for transmembrane iron transport [3], binding to the cellular iron efflux channel ferroportin, inducing its internalisation and degradation [4].”
BackgroundNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Hepcidin, ferritin and haptoglobin are produced in the liver as acutephase reactants, and their expression is dependent on interleukin-6 (IL-6) signalling [3,7,8].”
BackgroundSmolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultEmery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultSelf-citationGenovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultJones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultTime-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498 · cited 1×
“Hepcidin, ferritin and haptoglobin are produced in the liver as acutephase reactants, and their expression is dependent on interleukin-6 (IL-6) signalling [3,7,8].”
BackgroundKremer, J. M., Blanco, R., Brzosko, M., Burgos-Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 409 · cited 2×
“Mean age was slightly higher in this study than in the tocilizumab phase 3 pivotal trials; however, disease characteristics were similar [11-15].”
BackgroundResultIron Sequestration and Anemia of Inflammation
Ganz, T., & Nemeth, E. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.06.001 · Cited by 361 · cited 1×
“; licensee BioMed Central L Commons Attribution License (http://creativec reproduction in any medium, provided the or from macrophage reticuloendothelial stores [3,5].”
BackgroundMihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328 · cited 1×
“Tocilizumab is a humanised monoclonal antibody that inhibits IL-6 binding to its receptor [9].”
Background
Research works printed but not linked: 2
- McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: MEASURE: a translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation [abstract]. Ann Rheum Dis. 2011, 70 ((suppl)): 73-
- McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study. 2011, Chicago, IL: Presented at: 75th Annual Scientific Meeting of the American College of Rheumatology
Cited by
Weiss, G., Ganz, T., & Goodnough, L. T. (2019) · Blood · doi:10.1182/blood-2018-06-856500 · Cited by 1,219
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Nemeth, E., & Ganz, T. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.04.005 · Cited by 401
Hepcidin regulation in the anemia of inflammation
Wang, C.-Y., & Babitt, J. L. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000236 · Cited by 250
Bijlsma, J. W. J., Welsing, P. M. J., Woodworth, T. G., Middelink, L. M., Pethö-Schramm, A., Bernasconi, C., Borm, M. E. A., Wortel, C. H., ter Borg, E. J., Jahangier, Z. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30363-4 · Cited by 248
“Additionally, rapid and sustained control of the acute-phase response might result in a reduction of systemic extra-articular disease manifestations, such as anaemia, 47 osteoporosis, 48 and cardiovascular disease.”
Self-citation
Metadata
- Authors
- Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C.
- Affiliations
- Newcastle University (GB)
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Isaacs, John D
- Venue
- Arthritis Research & Therapy
- Published
- 2013-12-02
- Volume
- 15
- Issue
- 6
- Pages
- R204-R204
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC3978585
- OpenAlex
- W2114448779
- Cited by
- 105
- References
- 17
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 18 · 2020: 16 · 2019: 10 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 3 · 2014: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- tocilizumab, rheumatoid arthritis, IL-6 receptor inhibition, hepcidin, haptoglobin, ferritin, total iron binding capacity, iron metabolism, hemoglobin, C-reactive protein, acute phase proteins, systemic inflammation
- MeSH terms
- Adult, Aged, Anemia, Arthritis, Rheumatoid, Double-Blind Method, Female, Haptoglobins, Hemoglobins, Humans, Male, Middle Aged, Signal Transduction, Biomarkers, Interleukin-6, Antibodies, Monoclonal, Humanized, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. https://app.cochat.ai/papers/10.1186/ar4397
- The paper
- Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C. (2013). Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Research & Therapy. https://doi.org/10.1186/ar4397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.